𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Assessment of Inattention and Executive Dysfunction in Early Huntington’s Disease: The Atomoxetine Pilot Trial

✍ Scribed by L.J. Beglinger; W.H. Adams; H. Paulson; K. Duff; J.G. Fiedorowicz; J.M. Hanson; N. Ramza; D.R. Langbehn; J.S. Paulsen

Book ID
116800766
Publisher
Springer-Verlag
Year
2008
Tongue
English
Weight
38 KB
Volume
5
Category
Article
ISSN
1933-7213

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Atomoxetine for the treatment of executi
Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: A pilot open-label study
✍ Laura Marsh; Kevin Biglan; Melissa Gerstenhaber; James R. Williams 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 321 KB 👁 1 views

## Abstract Executive dysfunction (ED) is a prominent and often disabling feature of cognitive impairment in Parkinson's disease (PD). Few studies have examined treatments. Given the role of noradrenergic pathology in ED, atomoxetine, a norepinephrine reuptake inhibitor indicated for attention defi

Executive dysfunction using behavioral a
Executive dysfunction using behavioral assessment of the dysexecutive syndrome in Parkinson's disease
✍ Satoshi Kamei; Motohiko Hara; Kan Serizawa; Masato Murakami; Tomohiko Mizutani; 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 104 KB

## Abstract The objective of this study was to evaluate the executive dysfunction (ExD) in Parkinson's disease (PD) using the Behavioral Assessment of the Dysexecutive Syndrome (BADS), which provides a wide‐range assessment of ExD. The BADS and the Unified Parkinson's Disease Rating Scale (UPDRS) w